On July 30, Glaukos rose 9.49% in pre-market trading, trading at $177.0 per share. The stock surged after the company reported second-quarter results that far exceeded market expectations on both revenue and guidance fronts.

Specifically, Glaukos posted Q2 sales of $185.6 million, approximately 23% above the Wall Street consensus estimate of $150.9 million. Adjusted loss per share came in at $0.14, significantly better than the expected loss of $0.22, representing a 41.67% improvement from the year-ago loss of $0.24. Additionally, the company raised its full-year sales guidance to $680 million to $700 million, far surpassing the prior FactSet consensus of $630 million.

This marks the second consecutive quarter of substantial revenue outperformance, following Q1 sales of $150.6 million that also beat the $137 million estimate. On the institutional front, Truist raised its price target to $180 from $160 while maintaining a Buy rating, and Needham has also issued multiple target price increases, reflecting broadly bullish sentiment despite UBS recently downgrading the stock to Neutral.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)